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Growthhormonedeﬁciency(GHD)isawell-recognizedclinicalsyndromeinadults.However,duetothehighfrequencyofnormal
serum IGF-I levels in hypopituitary adults with GHD, it is now widely accepted that despite normal levels of total IGF-I, adults
clinicallysuspectedwithGHDwithintheappropriateclinicalsettingmustundergoGHprovocativetestingtoconﬁrmitsdiagnosis.
Although the insulin tolerance test (ITT) is labor intensive, contraindicated in the elderly and in adults with seizure disorders and
ischemic heart disease, can be unpleasant for the patient, and is potentially hazardous, this test remains the gold standard test
for the biochemical demonstration of GHD in adults. In contrast, with the unavailability of the GHRH and arginine test as the
alternative test to the ITT in the United States since 2008, the glucagon stimulation test (GST) has since been increasingly used in
theUnitedStatesbecauseofitsavailability,reproducibility,safety,lackofinﬂuencebygenderandhypothalamiccauseofGHD,and
relatively few contraindications. In this paper, we discuss our recommendations in performing this test, the potential drawbacks
in conducting and caveats in interpreting this test, and its future perspectives.
1.Introduction
Growth hormone deﬁciency (GHD) in adults is charac-
terized by alterations in body composition, carbohydrate
and lipid metabolism, bone mineral density, cardiovascular
risk proﬁle, and quality of life [1] .T r e a t m e n tw i t hG H
replacement has been shown to improve some, but not
all, of these abnormalities [2]. In contrast, untreated GHD
is associated with increased mortality and morbidity that
was previously observed in adults with hypopituitarism [3,
4]. These ﬁndings were substantiated in two large surveys
based on national Danish registries [5, 6]. In the study
by Stochholm et al., the authors reported that overall
mortality was increased in adults with GHD, with female
patientshavingsigniﬁcantlyhighermortalityratescompared
to males, and patients with childhood onset far exceeding
that of adult-onset GH deﬁcient patients [5]. In another
study published a year later, the same authors reported
that the morbidity of adults with GHD was approximately
threefold higher than that of a healthy population, with
implicated causes being due to infectious, cancer, endocrine,
neurological,eye,ear,circulatory,pulmonary,andurogenital
diseases, and trauma [6]. This result was independent of
gender and applied to patients with childhood-onset and
adult-onset GHD.
Current published guidelines recommend the evaluation
of adult GHD to be based on clinical ﬁndings, medical
history, and using the appropriate GH stimulation test
for biochemical conﬁrmation [7–9], with the exception of
patients with three or more pituitary hormone deﬁciencies
and low serum IGF-I levels [10]. Serum IGF-I levels should
not be used alone to diagnose adult GHD, and the maximum
or peak GH secretion following GH stimulation testing is
used as a surrogate of the capacity of the pituitary to release
GH. The insulin tolerance test (ITT) is generally considered
thegoldstandardtestfortheevaluationofGHdeﬁciencyand
has been endorsed by several consensus guidelines [7–9, 11].
However, this test is labor intensive, may be unpleasant for
some patients, has potential risks, and is contraindicated in
elderly patients and in patients with seizure disorders and
ischemic heart disease. Thus, there remains a real unmet
medical need for an alternative test to the ITT that is safe
yet reliable. For this reason, several other dynamic tests
have been proposed such as arginine (ARG), combined GH2 ISRN Endocrinology
releasing hormone plus ARG (GHRH-ARG), and levodopa
(L-DOPA) in spite of data indicating poor performance of
some of these tests for evaluation of adult GHD [10, 12]. A
potential alternative to the ITT is the glucagon stimulation
test (GST) that has been used extensively in the United
Kingdom [13] and is gradually gaining acceptance in the
United States [14].
2. Update on the Glucagon Stimulation
Test inDiagnosingAdult GHD
Following the publication of several validation studies
[12, 15–17] and recommendations from current consensus
guidelines [7–9, 11], the GHRH-ARG test has in recent
years emerged as the best and most reliable alternative
GH stimulation test to the ITT in diagnosing adult GHD.
However, when EMD Serono, Inc decided to discontinue the
manufacture of recombinant GHRH (Geref) in the United
States in July 2008 [18], this inevitably left a signiﬁcant gap
for an alternative reliable test for the evaluation of patients
suspectedtohaveGHDinplaceoftheGHRH-ARGtest.This
is particularly important for endocrinologists in the United
States who are not comfortable or do not have the necessary
logistic or staﬀ support to conduct ITTs in their oﬃce
or patients who have contraindications to hypoglycemia
in whom the ITT would be inappropriate. With the lack
of reliable GH stimulation tests available in the United
States, we have recommended the glucagon stimulation test
(GST) as the alternative test to the ITT for diagnosing adult
GHD based on its availability, reproducibility, safety, lack of
inﬂuence by gender and hypothalamic cause of GHD, and
relatively few contraindications [14].
Analyzing the data of 13,167 GH-deﬁcient patients
enrolled in the KIMS pharmacoepidemiological database
(Pﬁzer International Metabolic Database) from its inception
to the end of 2008, Brabant et al. addressed the question
of whether there were regional diﬀerences in the use of
diﬀerent biochemical tests to diagnose adult GHD in 6
large European countries and the United States [13]. This
analysis revealed striking regional variations in the approach
to GH stimulation testing. The ITT was found to be the
most popular test used in 44.3% of all countries but was
less popular (13.3%) in the United States ranking second
after the arginine test, whereas the GST was ranked third
in the United States, being the most popular in the United
Kingdom (29.9%) and the least popular in Germany and
the Netherlands (0.1%). However, the unavailability of the
GHRH-ARG test in the United States since 2008 has resulted
in a change in recent years with the GST being more
frequently used as the alternative test to the ITT [14].
The use of the GST for the assessment of GH reserve was
ﬁrst described in 1969 by Mitchell et al. [19]. Since then,
the GST has been shown by various investigators to have
a GH secretory potency that is similar to or only slightly
less than the ITT, suggesting that it is more reliable than
other classic agents such as ARG or clonidine for separating
GHD patients from normal subjects [20–24]. The true
mechanism by which glucagon induces GH release remains
unclear. Some of the hypothesized mechanisms include the
glycemic ﬂuctuations during the test where blood glucose
levels increase initially before decreasing later in the test [25],
the generation of a peptidyl fragment associated with the
GH- and ACTH-releasing activity [26] and the induction
of norepinephrine secretion in stimulating GH release via
α-receptors [27]. It has also been previously demonstrated
that glucagon stimulates GH release more eﬀectively when
administered intramuscularly or subcutaneously as opposed
to the intravenous route [23].
The three studies utilizing the GST by Gomez et al.
[28], Conceicao et al. [22], and Berg et al. [21]e v a l u a t e d
GHD in patients with pituitary disorders. The ﬁrst two
studies [22, 28] were prospective studies that compared
the diagnostic characteristics of GST to ITT and included
a control group which was matched for age and sex in
both studies and for body mass index (BMI) in one study
[28]. Using receiver-operator curve (ROC) analysis, both
studies proposed a peak GH cutoﬀ value of 3ng/mL as
the best cutpoint with the highest combined sensitivity and
speciﬁcity to diﬀerentiate between patients with GHD and
healthy controls [28, 29]. Additionally, Gomez et al. [28]
found no correlation among age, sex, and BMI with peak
GH levels in patients with hypopituitarism, but there was
a signiﬁcant negative correlation between age (r =− 0.389,
P = 0.0075) and BMI (r =− 0.329, P = 0.025) with peak
GH levels in healthy controls. It is important to note that the
GH-deﬁcient adults in this study had higher BMIs than the
healthy controls; nevertheless, these data suggest that there is
a potential association between relative, but not functional,
GH deﬁciency of obesity and aging with BMI. By contrast,
the study by Conceicao et al. [22] demonstrated that peak
GH levels were not aﬀected by age in either the control or
patientgroup,andthattherewerenogenderdiﬀerences.Itis,
however, noteworthy that in the study by Gomez et al. [28],
the dose of glucagon administered was 1mg for subjects that
weighed 90kg or less and 1.5mg for subjects that weighed
more than 90kg whereas in the study by Conceicao et al.
[22], all subjects received 1mg of glucagon. Furthermore,
there were slightly more females in the study by Conceicao
et al. [22] compared to Gomez et al. [28] study. On the
other hand, the study by Berg et al. was a retrospective study
that revealed an optimal peak GH cutoﬀ value of 2.5ng/mL
with 95% sensitivity and 79% speciﬁcity using ROC analysis
[21]. This study also reported lower peak GH levels with
GST compared to ITT (5.1 versus 6.7ng/mL, P<0.01)
but a signiﬁcant positive correlation between peak GH levels
during ITT and GST (r = 0.88, P<0.0001). Additionally, no
correlation between BMI and age to peak GH responses was
observed, peak GH responses occurred mainly between 120
and 180 min consistent with previous studies [27, 30], and
that, overall, the GST was a well-tolerated test. Nevertheless,
these [21, 22, 28] and previous studies [20, 23, 24, 31] did
not speciﬁcally evaluate patients with glucose intolerance
and frank diabetes, and for this reason, the characteristic
of the GST and its reliability in testing for GHD in this
population remains unclear. This is especially important
since performing ITT in patients with diabetes is usually
challenging and may not be safe especially if large insulinISRN Endocrinology 3
Table 1: Recommended protocol for performing the GST in adults.
Contraindications:
Malnourished patients or patients who have not eaten for >48h
Precautions:
Patients may feel nauseous during and after the test
(administration of intravenous antiemetics can be considered)
Late hypoglycaemia may occur (patients should be advised to
eat small and frequent meals after the completion of the test)
Procedure:
Ensure patient is fasted from midnight
Weigh patient
Patient in recumbent position and intravenous cannula inserted
for intravenous access between 8am to 9am
Glucagon administered intramuscularly 1mg (1.5mg if patient
weighs more than 90kg)
Sampling and measurements:
Serum GH and capillary blood glucose levels at 0, 30, 60, 90,
120, 150, 180, 210, and 240mins
Normal response:
Blood glucose usually rises to peak around 90mins and then
gradually declines (not used to interpret the test)
Serum GH: peak GH levels tend to occur between 120 to
180mins with GH levels peaking to above 3ng/mL
Interpretation:
In adults with GHD, peak GH levels fail to rise above 3ng/mL
doses are required to achieve hypoglycaemia in patients with
underlying insulin resistance.
3. Other Considerations in Performing and
Interpretingthe Dataof the GST
The diagnosis of adult GHD has proved to be challenging
because of the lack of a single biological endpoint such
as growth failure, and, therefore, the conﬁrmation of adult
GHD largely depends on biochemical provocative testing.
Clearly, there is no ideal stimulation test and we recommend
thatthedecision toembarkonastimulation test,todiagnose
adult GHD must factor in the appropriate clinical context
of each individual patient together with the number of
pituitary hormone deﬁciencies plus serum IGF-I level [10],
the validity of the chosen test and its appropriate cutoﬀ
limits, the sensitivity of the GH assay, and the availability of
local resources and expertise.
The GST is a simple and safe test to perform (Table 1).
Glucagon is readily accessible because it is widely available
for treating hypoglycemic episodes in patients with diabetes.
In addition, glucagon is relatively inexpensive (the current
average wholesale price of recombinant DNA glucagon is
approximately $50–$70 per single 1mg dose, while for Geref
and ARG is approximately $80–$130 per single 50μga n d
$10–$12 per single 30g dose, resp.). Glucagon appears to
be welltolerated and is only relatively contraindicated in
patients with malnourishment or patients who have not
eaten for more than 48 hours due to concern of prolonged
hypoglycemia and those with pheochromocytoma in whom
a signiﬁcant exacerbation of blood pressure may be observed
[25].
The GST was initially described as a 4-hour test in older
studies [32, 33] ,b u tm o r er e c e n ts t u d i e sh a v es u g g e s t e d
that the test could be shortened to a 3-hour test, and that
serum GH levels can be evaluated between 3 to 5 time
points only (0, 90, 120, 150, and 180mins) as the majority
of GH peaks occurred between 120 and 180mins (85%)
[27, 31]. In a study by Orme et al. comparing standard and
simpliﬁed GST (0, 150 and 180min), 75% of discordant GH
results were due to a peak GH level occurring at 210min
[31]. Accordingly, the authors proposed that the diagnostic
utility of the simpliﬁed GST could be improved further
by drawing an additional blood sample at 210min when
assessing GH deﬁciency. The audit by Leong et al. [27]i s
the largest study that assessed patients with hypothalamic-
pituitary disease whom had undergone the GST, and they
reported that the test could be shortened by omitting the
240-min blood sample. Among 414 patients who underwent
GSTs, the majority of peak GH levels occurred between
120 and 180min (85%) and 5 patients had their peak
GH levels recorded at 240min. Hence, it is still not clear
whether the ideal timing of the GST is 3 versus 4 hours,
and continuing the test for 4 hours may be advisable, at least
until there are more deﬁnitive data available. This also allows
the monitoring for late hypoglycemia, although truly low
bloodglucoselevelsarenotcommon.Whilethelowestblood
glucose level with the GST in the literature was reported at
37mg/dL [19], in our experience [34], we rarely observed
blood glucose levels falling below 40mg/dL with this test.
The occurrence of hypoglycemia reported in the literature
with blood glucose levels lower than 40mg/dL during GSTs
is also rare event [21, 27].
The common sideeﬀects in patients with hypothalamic-
pituitary disease that underwent testing with the GST
included nausea, vomiting, and headaches and have been
reported to range from less than 10 [21] to 34% [27]. In a
study of 97 normal subjects, mild nausea in approximately
30% of the subjects and transient vomiting and retching in
about 10% of the subjects were the only side eﬀects that were
noted[35],whereasinourexperienceof143GSTsperformed
at 4 large academic centers in the United States, the main
side eﬀects reported were nausea (41%), fatigue, headaches,
w e a k n e s s ,a n dh u n g e r( 1 2 % )[ 34].
LikeotherGHstimulationtests,therearealsolimitations
associated with the GST. The 3- or 4-hour GST is still
longer than many other GH stimulation tests and requires
an intramuscular injection which may not appeal to some
patients.However,asthereisarelationshipbetweenpeakGH
response to GHRH-ARG stimulation and ambient glucose
levels [29], it is unclear whether hyperglycemia may play
a part in inﬂuencing the peak GH response to glucagon
stimulation. Furthermore, no peak GH responses have been
studied using the GST in normal controls over the age
of 70 years, and none of the previous studies included
patients with frank diabetes. Therefore, it is not known
whether testing using the GST in subjects with diabetes is
valid. Hence, caution should be exercised when interpreting4 ISRN Endocrinology
normal GST results in the patients with diabetes. If the
suspicion of GHD remains high in these patients, it is
reasonable to consider using a second GH stimulation test.
Finally, while it is accepted that a peak GH response of
3ng/mL or less is the best cutpoint to diagnose adult GHD
using the GST [22, 28], there remains a lack of consensus
over a peak GH response between 3ng/mL and 10ng/mL,
and further studies are required to address this.
Other provocative tests that have been proposed include
ARG alone and GH secretagogues. ARG alone has been
shown to be less reliable than the ITT or GHRH-ARG [12]
and the mean peak GH response to ARG alone is lower
t h a ni nt h eI T To rG S T ,e v e ni nn o r m a ll e a ns u b j e c t s
[24]. The diagnostic reliability of ARG alone has been
previously questioned [12, 20]. Thus, we recommend that
ARG alone should only be considered if the ITT and
the GST is contraindicated or if glucagon is unavailable.
If this test is used, appropriately low peak GH cutoﬀs
should be employed (for 95% sensitivity: 1.4μg/L, for 95%
speciﬁcity: 0.21μg/L, and to minimize misclassiﬁcation in
either direction: 0.4μg/L) [12]. In contrast, the reliability of
testingwithGHsecretagoguessuchasGH-releasingpeptide-
2 alone [36], GH-releasing peptide-6 alone, and combined
GH-releasingpeptide-6plusGHRH[37]incomparisonwith
the ITT has also been demonstrated. These agents utilize
the same concept as the GHRH-ARG test in stimulating
pituitary GH release by mimicking the activity of the natural
GH secretagogue receptor ligand (i.e., ghrelin) and appear
to demonstrate a good safety proﬁle with relatively few
contraindications [38]. The limitation, however, of these
GH secretagogues is that these agents are more likely to
explore the pituitary somatotroph releasable pool and might
potentially induce misleadingly normal peak GH responses
in hypothalamic GHD [39]. Furthermore, these agents are
not readily available in many countries including the United
States.
4.FuturePerspectives
Recent studies have indicated that further reﬁnements to the
GST may still be required to improve the sensitivity and
speciﬁcity of this test. A study by Micmacher et al. [40]
demonstrated in a group of healthy men above 50-year old
that GH secretion in response to the GST, but not with the
ITT, correlated to physiological spontaneous GH secretion.
These data indicate that GH response to the GST reﬂects
the endogenous GH spontaneous secretion and poses the
question as to whether the cutpoints of peak GH response
to the GST should be agedependent. More recently, we have
reported a 1-year experience of GSTs conducted from 4
large academic centers in the United States and explored the
potential of the GST in testing the hypothalamic-pituitary-
a d r e n a la x i s[ 34]. In this study, we found that the majority
of GH peaks occurred between 120 and 180mins (78%) and
that there was a negative correlation between fasting glucose
(r =− 0.24, P<0.01) and BMI (r =− 0.37, P<0.01) with
peakGHlevels.Whencomparedwiththe250μgcosyntropin
stimulation test using a cutpoint of 18μg/dL, peak cortisol
levels with GSTs were lower (P<0.02) and had higher
failure rates (44.4% versus 33.3%), and the 120-min peak
cortisol of 16.5μg/dL achieved 83.3% sensitivity and 75%
speciﬁcity using ROC analysis. Overall, the GST was well
tolerated and can be performed as an outpatient; however,
further studies are required to determine whether GSTs may
falsely diagnose GHD in patients with fasting hyperglycemia,
and/or high BMIs. Thus, to improve the diagnostic reliability
oftheGSTespeciallyinpatientswithglucoseintoleranceand
in those with high BMIs, a priming agent may be required
to combine with the GST with appropriate cutpoints to
improve its sensitivity and speciﬁcity, similar to the GHRH
in priming the ARG test. Until such data becomes available,
werecommendthatasecondGHstimulationtestshouldstill
be considered for such patients.
In conclusion, in line with recently published consensus
guidelines [7–9, 11], the ITT should remain as the test of ref-
erenceduetoitsgreatestdiagnosticaccuracy,eveninpatients
with suspected hypothalamic GHRH deﬁcit. We recommend
the GST as the alternative test to the ITT for diagnosing
adult GHD because of its availability, reproducibility, safety,
lack of inﬂuence by gender and hypothalamic cause of GHD,
and relatively few contraindications. Despite some studies
demonstrating the comparability of the GST to the ITT in
assessing the hypothalamic-pituitary-adrenal axis [41, 42],
further larger, well-controlled studies are still needed to
conﬁrm the reliability of the GST in assessing this axis. If the
GST can be shown to reliably distinguish adrenal suﬃciency
from insuﬃciency, then the ability of assessing both the GH
and cortisol reserve simultaneously, just as in the ITT, would
make this test even more appealing. While previous studies
have shown that the GST could be shortened from 4 to 3
hours and yet maintain its diagnostic utility [27, 31], until
further data becomes available, we would still recommend
that the GST be conducted over 4 hours with measurements
every30minforserumGHandcapillarybloodglucoselevels
primarily to ensure that delayed peak GH responses and late
hypoglycemia are not missed.
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